Among patients with stage III colon cancer, patients aged 70 or older were less tolerant of adjuvant oxaliplatin/flouropyrimidine therapy, in addition to having poorer relapse-free interval rates on the regimen, according to findings from a large subgroup analysis of the phase III TOSCA trial presented by Lonardi et al at the ESMO Virtual Congress 2020.
Nivolumab monotherapy showed high response and disease control rates in patients with pathogenic exonuclease domain POLE (edPOLE)-mutated, mismatch repair (MMR)-proficient advanced tumors containing confirmed pathogenic mutations, according to findings presented by Benoit J.C. Rousseau, MD, PhD, at the ESMO Virtual Congress 2020.
Findings from two meta-analyses designed to summarize quality-of-life data on patients receiving immune checkpoint inhibitor therapy for cancer were presented by Gonzalez et al at the ESMO Virtual Congress 2020. These meta-analyses found that patients receiving immune checkpoint inhibitors had better quality of life than patients receiving non–immune checkpoint inhibitor treatment.
At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, Pamela Allen, MD, described recent trials on therapeutic approaches for Hodgkin lymphoma.